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Abstract
Background: The mitogen-activated protein kinase (MAPK) signaling pathway participates in several steps of
tumour development and is considered a prominent therapeutic target for the design of chemotherapeutic agents.
We evaluated the expressions of extracellular signal-regulated kinase (ERK), mitogen-activated protein kinase (MEK),
an upstream regulator of ERK, and Raf kinase inhibitor protein (RKIP), and investigated correlations of these
expressions with clinicopathological features and outcomes in gastric cancer.
Methods: Tumour samples were obtained from 105 patients with gastric adenocarcinomas who underwent radical
gastrectomy. The expressions of phosphorylated ERK (p-ERK), phosphorylated MEK (p-MEK), and RKIP were analysed
by immunohistochemical staining.
Results: Expression of RKIP, p-MEK, and p-ERK was found in 69 (66%), 54 (51%), and 64 (61%) of all tumours,
respectively. RKIP expression negatively correlated with the depth of invasion (p < 0.001), lymph node involvement
(p = 0.028), and Union for International Cancer Control (UICC) stage (p = 0.007). RKIP expression was associated
with significantly longer relapse-free survival (RFS) (p = 0.0033), whereas p-MEK was not (p = 0.79). Patients with p-
ERK expression had slightly, but not significantly shorter RFS than those without such expression (p = 0.054).
Patients with positive p-ERK and negative RKIP expression had significantly shorter RFS than the other patients (p <
0.001). The combination of RKIP and p-ERK expression was an independent prognostic factor (hazard ratio, 2.4; 95%
confidence interval, 1.3 - 4.6; p = 0.008).
Conclusions: Our results demonstrated that loss of RKIP was associated with tumour progression and poor
survival. Negative RKIP expression combined with positive p-ERK expression was an independent predictor of poor
outcomes in patients with gastric cancer.
Background
Gastric cancer remains the second most common cause
of cancer-related death worldwide [1,2]. Many Asian
countries, including China, Japan, and Korea, still have
very high incidences of and mortality from gastric can-
cer. Despite progress in early diagnosis of gastric cancer,
many patients present with unresectable, locally
advanced, or metastatic disease associated with an extre-
mely poor prognosis. Most cases of advanced gastric
cancer remain incurable, with a median survival of only
6-12 months even in patients who receive intensive che-
motherapy [3-7]. Trastuzumab, a monoclonal antibody
against human epidermal growth factor receptor 2
(HER2), is therapeutically effective in gastric cancer.
However, 22% of all advanced or metastatic gastric can-
cers showed HER2 overexpression in one clinical trial
[8]. A better understanding of the etiologic factors and
molecular mechanisms underlying the pathogenesis of
gastric cancer is thus essential for improved outcomes.
Mitogen-activated protein kinases (MAPKs) are ser-
ine/threonine kinases that are activated in response to a
variety of external signals. Extracellular signal-regulated
kinases (ERK) comprise one subclass of MAPKs that
can be activated by various receptor tyrosine kinases,
cytokine receptors, G proteins, and oncogene products
through phosphorylation by MAPKs or ERK-activated
protein kinase (MEK). On activation of the MAPK cas-
cade, ERK is phosphorylated by MEK on threonine and
tyrosine residues and translocates from the cytoplasm to
nucleus, where ERK phosphorylates several nuclear
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targets, including transcription factors [9]. After stimula-
tion, ERK is phosphorylated by MEK, from which it
then dissociates. The MEK-mediated phosphorylation of
ERK, especially tyrosine phosphorylation, is prerequisite
for the dissociation of ERK from MEK. Dissociated ERK
then enters the nucleus by either passive diffusion or
active transport mechanisms [9]. ERK is implicated in
various cellular processes, including proliferation, differ-
entiation, apoptosis, and transformation.
Raf kinase inhibitor protein (RKIP), also termed phos-
phatidylethanolamine binding protein (PEBP)-1, is a 20-25
kDa globular protein that belongs to the PEBP family,
encompassing more than 400 members [10]. RKIP is sup-
posed to bind to Raf-1 and inhibit Raf-1-mediated phos-
phorylation of MEK [11,12]. As a modulator of signaling
pathways, RKIP also affects various cellular processes [13].
Deviant control of the MAPK cascade has been implicated
in the development of human neurodegenerative diseases,
such as Alzheimer’s disease, Parkinson’s disease, and
amyotrophic lateral sclerosis, as well as various types of
human cancer. Many Ras and B-Raf mutations occur in
human cancer [14].
The purpose of this study was to investigate the
expression of phosphorylated ERK (p-ERK) and its
upstream regulating signals such as phosphorylated
MEK (p-MEK) and RKIP in human gastric cancer and
to evaluate relations of the expressions of these proteins
to clinicopathological variables and outcomes.
Methods
Patients
February 2004 through December 2007 we studied 105
patients who underwent curative gastrectomy (R0) for
primary gastric adenocarcinomas penetrating beyond the
muscularis mucosa at the Department of Esophagogas-
tric Surgery, Tokyo Medical and Dental University. This
study was conducted due to Declaration of Helsinki
[15], and approved by Institutional Review Board of the
Tokyo Medical and Dental university. Each tumour was
classified according to the tumour-node-metastasis
(TNM) classification recommended by the Union for
International Cancer Control (UICC). All patients were
evaluated for recurrent disease by examinations of
tumour markers or by diagnostic imaging, including
computed tomography, ultrasonography, magnetic reso-
nance imaging, and endoscopy, every 3-6 months. No
patient received neoadjuvant therapy. The median fol-
low-up time was 55 months (range, 37-84). Recurrent
disease was diagnosed in 45 patients (43%) and was the
cause of death in 40 (38%) patients.
Immunostaining of p-MEK and p-ERK and RKIP
Immunohistochemical staining was carried out by the
streptavitin-biotin method using a Histofine SAB-PO kit
(Nichirei Co., Tokyo, Japan). Polyclonal rabbit antibody
against p-ERK was purchased from Abcam® (Cam-
bridge, UK), monoclonal Rabbit antibody against p-MEK
1/2 (Ser221) was purchased from Cell Signaling Tech-
nology, Inc. (Beverly, MA, USA), and RKIP antibody
was purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA). All available haematoxylin-and-
eosin-stained slides of the surgical specimens were
reviewed. For each case, representative paraffin blocks
were selected for immunohistochemical studies. Three-
micrometer-thick sections were cut from each formalin-
fixed, paraffin-embedded tissue block. After deparaffini-
sation and rehydration, antigen retrieval treatment was
carried out at 98°C (microwave) for 15 min in 10
mmolL sodium citrate buffer (pH 6.0), followed by treat-
ment with 3% hydrogen peroxide for 15 min to quench
endogenous peroxidase activity. Nonspecific binding was
blocked by treating the slides with 5% EzBlock (includ-
ing 10% normal goat serum) for 10 min at room tem-
perature. The slides were incubated with primary
antibodies including p-ERK (dilution 1:50), p-MEK
(1:50), and RKIP (1:100) overnight at 4°C. Immunode-
tection was performed by the conventional streptavidin-
biotin method with peroxidase-labeled Nichirei SAB-PO
kits. Diaminobenzidine substrate was used for colour
development. The slides were counterstained with 1%
Mayer’s haematoxylin. Expression levels of p-ERK, p-
MEK, and RKIP were classified into groups based on
staining intensity and positive frequency. We counted
stained cells under a microscope to derive the scores.
The cytoplasmic and nuclear staining patterns were
separately quantified, using a semiquantitative system to
evaluate and grade the immunostaining pattern, as suc-
cessfully applied by others [16]. Staining intensity was
scored into four grades: 0 (none), 1 (weak positive), 2
(moderate positive), and 3 (strong positive). Staining
extent (positive frequency) was also scored into four
grades: 0 for complete absence of staining, 1 for < 10%,
2 for 10% to 50%, and 3 for tumours with staining of
50% or more cells. Composite scores were derived by
multiplying the intensity score by the staining extent
score. For statistical analysis, composite scores of ≥4
were defined as cytoplasmic expression positive, and
scores of < 4 were considered negative. We assessed the
cytoplasmic expressions of RKIP and MEK and the
nuclear expression of ERK as described previously
[16,17].
Statistical analysis
The c2 test was used to test possible associations
between the expression of p-ERK, p-MEK, or RKIP and
clinicopathological factors. It was also used to assess
correlations between p-ERK, p-MEK, and RKIP expres-
sions. Kaplan-Meier curves were plotted to assess the
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relations of p-ERK, p-MEK, and RKIP expressions to
relapse-free survival (RFS). Survival curves were com-
pared using the log-rank-test. P-values of less than 0.05
(P < 0.05) were considered to indicate statistical signifi-
cance. Multivariate Cox proportional-hazards regression
models were used to assess the prognostic significance
of p-ERK, p-MEK, and RKIP expressions and of several
clinicopathological factors. Statistical analysis was car-
ried out with the use of SPSS Base, version 17.0 and
SPSS Advanced models, version 17.0 (SPSS Inc., Chi-
cago, IL, USA) software.
Results
RKIP, p-MEK, and p-ERK were respectively expressed
by 69 (66%), 54 (51%), and 64 (61%) of all tumours (Fig-
ure 1a-c). RKIP expression was mainly observed in the
cytoplasm of tumour or non-tumour cells. Expressions
of p-MEK and p-ERK were found in both the cytoplasm
and nucleus. Expressions of RKIP, p-MEK, and p-ERK
were respectively detected in 5 (19%), 9 (35%), and 21
(81%) of 26 metastatic lymph nodes obtained from
patients with recurrent disease (Figure 1d-f). Expression
of p-ERK was found mainly in the nuclei of metastatic
tumour cells. These proteins were also detected in
tumour cells associated with venous invasion (Figure 1g-
i). No p-ERK or p-MEK staining was detected in normal
gastric mucosa. The expression of p-MEK positively cor-
related with the expressions of RKIP (p = 0.042) and p-
ERK (p = 0.007), whereas there was no relation between
RKIP and p-ERK expressions (p = 0.98) (Table 1). RKIP
expression negatively correlated with the depth of inva-
sion (p < 0.001), lymph node involvement (p = 0.028),
and UICC stage (p = 0.007). RKIP was more commonly
found in differentiated type than in undifferentiated type
Figure 1 Representative gastric carcinomas showing immunostaining for RKIP predominantly in the cytoplasm, (a), immunostaining
for p-MEK predominantly in the cytoplasm (b), and immunostaining for p-ERK in the nucleus and the cytoplasm (c); magnification,
2×. The upper inset shows a surface site of tumour and the lower inset shows a site of deep invasion (a - c); magnification, 40×. Metastatic
lymph nodes showing immunostaining for RKIP in the cytoplasm (d), for p-MEK in the nucleus (e), and for p-ERK with strong intensity in the
nucleus (f); magnification, 40×. Tumour cells associated with venous invasion showing immunostaining for RKIP with weak intensity (g), for p-
MEK (h), and for p-ERK in the nucleus (i); magnification, 40×.
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tumours (p = 0.042). The expressions of p-ERK and p-
MEK significantly correlated with gender (p = 0.027, p =
0.036, respectively), but were not related to any other
clinicopathological factor (Table 2).
RKIP expression was associated with significantly
longer RFS (p = 0.003), whereas p-MEK was not (p =
0.79). The presence of p-ERK expression was associated
with slightly, but not significantly shorter RFS than the
absence of such expression (p = 0.054) (Table 3).
Patients with positive p-ERK and negative RKIP expres-
sion had significantly shorter RFS than the other
patients (p < 0.001) (Figure 2). The prognostic relevance
of positive p-ERK expression combined with negative
RKIP expression was therefore assessed using a multi-
variate proportional-hazards model adjusted for estab-
lished clinical prognostic factors (i.e., age, gender,
histopathology, depth of invasion, lymph node involve-
ment). The combination of RKIP and p-ERK expression
was found to be an independent prognostic factor
(hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.3
- 4.6; p = 0.008). Histopathological type and depth of
invasion were also independent prognostic factors (HR,
2.1; 95% CI, 1.0 - 4.2; p = 0.043 and HR, 4.7; 95% CI,
1.0-22; p = 0.048, respectively) (Table 3).
Discussion
Our study showed that loss of RKIP expression and
overexpression of ERK in the MAPK signaling pathway
Table 1 Correlations among RKIP, p-MEK, and p-ERK
expressions
p-MEK p-ERK
negative positive p negative positive p
RKIP
negative 25 16 0.042 14 27 0.98
positive 26 38 22 41
p-MEK
negative 24 27 0.007
positive 12 42
Table 2 Clinicopathological factors and expression of RKIP, p-MEK, and p-ERK
cytoplasmic cytoplasmic nuclear
RKIP p-MEK p-ERK
n negative positive p negative positive p negative positive p
Age
> 70 46 16 30 0.43 20 26 0.36 17 29 0.61
≦ 70 59 25 34 31 28 19 40
Gender
female 21 6 15 0.40 15 6 0.036 12 9 0.027
male 84 35 49 36 48 24 60
Histopathology (WHO)
pap 12 3 9 0.20 5 7 0.34 5 7 0.99
tub1 15 2 13 5 10 5 10
tub2 27 11 16 13 14 10 17
por1 14 7 7 5 9 4 10
por2/sig 31 15 16 20 11 10 21
muc 6 3 3 3 3 2 4
Histopathology (2 groups)
differentiated 54 16 38 0.042 23 31 0.21 20 34 0.54
undifferentiated 51 25 26 28 23 16 35
Depth of invasion
T1b/2 32 4 28 < 0.001 14 18 0.51 12 20 0.65
T3/4 73 37 36 37 36 24 49
LN metastasis
negative (N0) 35 8 27 0.028 16 19 0.68 15 20 0.19
positive (N1/2/3) 70 33 37 35 35 21 49
Distant metastasis or recurrence
negative 68 19 49 0.002 33 35 0.99 27 41 0.17
positive 37 22 15 18 19 9 28
Stage
I/II 53 14 39 0.007 24 29 0.50 19 34 0.73
III/IV 52 27 25 27 25 17 35
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were associated with survival in patients with invasive
gastric cancer. Few previous studies have examined cor-
relations among RKIP, MEK, and ERK expressions in
samples of human cancer. RKIP is considered to be a
signal transduction modulator and metastasis suppressor
that inhibits the upper MAPK signaling pathway. RKIP
binds to Raf-1 and prevents MAP kinase signaling in
response to growth factors [11,13]. Loss of RKIP is
thought to induce activation of MEK and ERK; however,
evidence supporting this negative correlation was not
found in the present study. RKIP is missing or depleted
in a number of metastatic tumours [10], especially
human breast [18] and colorectal cancer [19]. In the
present study, RKIP expression was lost in many meta-
static lymph nodes, consistent with the results of those
investigations. In the patients with gastrointestinal stro-
mal tumours (GISTs), RKIP expression levels correlate
with clinical-pathological factors, and loss of RKIP
expression is associated with poor survival [20]. RKIP
expression has been reported to be lower in gastric car-
cinoma than in normal gastric tissue [21]. Loss of cyto-
plasmic RKIP was significantly linked to poor survival of
patients with gastric cancer [16,22]. Our findings are
consistent with those of previous studies. Cytoplasmic
RKIP expression has been found to positively correlate
with survival in intestinal type gastric adenocarcinoma,
but not in diffuse type [16].
The MAPK pathway, signal transducer and activator
of transcription 3 (STAT3) pathway, and phosphatidyli-
nositol 3-kinase (PI3K)/AKT/mammalian target of rapa-
mycin (m-TOR) pathway are signaling pathways that
regulate fundamental cellular processes such as prolif-
eration, differentiation, angiogenesis, survival, apoptosis,
and migration. Although each pathway is conceptually
linear, considerable cross-talk occurs between the
MAPK pathway and other signaling cascades [23].
MAPK signaling plays a central role in coordinating cell
re-entry, cell survival and mortality, and cell invasion in
Table 3 Prognostic factors in multivariate Cox proportional-hazards regression models for RFS
Univariatea) Multivariate 1b) Multivariate 2c)
5-yr RFSd) p HR 95%CI p HR 95% CI p
Age
> 70 73





differentiated 79 1.0 1.0
undifferentiated 42 0.001 2.2 1.1 - 4.4 0.035 2.1 1.0 - 4.2 0.043
Depth of invasion
T1/2 93 1.0 1.0
T3/4 46 0.002 4.8 1.0 - 23 0.048 4.7 1.0 - 22 0.048
Lymph node metastasis
negative (N0) 83 1.0 1.0
positive (N1/2/3) 48 0.002 1.6 0.59 - 4.5 0.34 1.6 0.59 - 4.5 0.35
RKIP
positive 66 1.0






positive 49 0.054 2.0 0.93 - 4.2 0.078
Combined expression
RKIP(+) or p-ERK(-) 69 1.0
RKIP(-) and p-ERK(+) 33 < 0.001 2.4 1.3 - 4.6 0.008
a) log-rank test
b) analysed factors: Histopathology, Depth of invasion, Lymph node metastasis, RKIP, and pERK
c) analysed factors: Histopathology, Depth of invasion, Lymph node metastasis, and Combined expression of RKIP and pERK
d) the rate of 5-year relapse free survival
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response to growth factors. Expression of ERK is
increased in gastric cancer tissue, and overexpression of
ERK positively correlates with clinicopathological char-
acteristics such as serosal invasion, lymph node involve-
ment, and TNM stage [24]. In our study, overexpression
of p-MEK and overexpression of p-ERK were observed
in high proportions of tumours. Expression of p-ERK
was slightly, but not significantly associated with survi-
val, although p-MEK was not associated. The localiza-
tion of p-ERK is an important factor in tumour
progression, because activated ERK characteristically
accumulates in the nucleus and transports extracellular
stimuli from the cell surface to the nucleus in intracellu-
lar signal transducing pathways. MEK-catalysed ERK
phosphorylation is necessary but not sufficient for the
full nuclear localization response. Nuclear localization of
phosphorylated ERK is affected by other proteins such
as dual specificity phosphatase [25]. In colorectal cancer
cells, the trafficking protein particle complex 4
(TRAPPC4) modulates the location of p-ERK to activate
the relevant signaling pathway [26]. On the other hand,
other studies reported that MAPK activity is rather sup-
pressed in human gastric adenocarcinoma [27,28]. The
complex multiple signaling MAPK pathway accepts
many positive or negative stimuli, including negative
auto-feedback mechanisms, and ERK activation is inhib-
ited by components of the network, such as protein tyr-
osine phosphatase (PTP) or other MAPK phosphatases
activated by transcription factors [29]. Consequently,
ERK might not necessarily be activated when the direct
upstream regulator MEK is active. Raf/MEK/ERK signal-
ing pathway seems to be affected also by various regula-
tors or negative feedback mechanisms. Therefore, the
combined expression of upstream regulator and down-
stream effector may have an important impact on survi-
val. In the present study, patients with negative RKIP
expression had poorer survival (5-year RFS = 44%) than
those with only positive RKIP expression (66%), patients
with positive p-ERK expression had similar survival
(49%) to those with negative p-ERK expression (75%),
and patients with a combination of negative RKIP
expression and positive p-ERK expression had poorer
survival (33%) than those with positive RKIP expression
or negative p-ERK expression (69%). In addition, nega-
tive RKIP and positive p-ERK expression was observed
in 18 (69%) of 26 metastatic lymph nodes obtained from
patients with recurrent disease. Our findings suggest
that combined expression might be an independent
prognostic factor.
ERK or MEK activation results from the sequential
activation of a series of protein kinases, including Raf-1,
and the up-regulating protein RAS. Approximately 30%
of all human tumours have an activating mutation in a
RAS gene. In particular, KRAS mutations are among the
most common genetic abnormalities in several types of
human cancer, including pancreatic cancer, colon can-
cer, and lung cancer [30]. In contrast, RAS mutations
have been found in only a small proportion of human
gastric cancers [31], implicating other mechanisms in
the activation of RAS signaling in gastric tumourigen-
esis. B-RAF mutations are more narrowly distributed
and are prevalent in a few specific malignancies, includ-
ing melanoma, papillary thyroid cancer, and low-grade
ovarian cancer, but are not found in gastric cancer
[32,33]. In the present study, we focused on more down-
stream proteins such as MEK, ERK, and RAF inhibitors
such as RKIP, and did not measure RAS or RAF expres-
sion. We previously showed that high expression of
HER1 or HER3, which are upstream components of the
RAS/RAF/MAPK and other tyrosine kinase pathways,
was associated with poor survival in gastric cancer [34].
In addition, we reported that the expression of m-TOR
in another pathway involving HER was related to survi-
val in gastric cancer [35]. Signaling pathways involving
tyrosine kinase receptors seem to be intimately related
to invasion, metastasis, and outcomes in gastric cancer.
However, anticancer agents that inhibit these pathways
are not utilized clinically, with the exception of trastuzu-
mab, an HER2 antagonist. Molecules implicated in
downstream signaling pathways, such as ERK, may be
targets for chemotherapy in advanced or metastatic gas-
tric cancer. Small-molecule inhibitors of the MAPK cas-
cade that are designed to target various steps of this
Figure 2 Kaplan-Meier curves for the relapse-free survival of
patients with expression of RKIP and p-ERK.
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pathway, such as MEK inhibitor and Raf inhibitor, have
entered clinical trials, but direct ERK inhibitors have yet
to be evaluated [36-39].
Many pathological and molecular assays suggest that
gastric cancer is a heterogeneous disease. However,
despite evidence indicating that gastric cancer is charac-
terized by interindividual differences in tumour progres-
sion, histopathological features, and treatment response,
a “one size fits all” approach to analysis has been used
in many studies of gastric cancer, resulting in inconsis-
tent outcomes [40]. The procurement of specimens
from multiple sites may be essential when assessing het-
erogeneous tumours. We counted stained cancer cells in
at least three fields per section, including the deepest
site invaded by cancer cells, the surface of the lesion,
and an intermediate zone. Staining for RKIP, p-MEK, or
p-ERK often differed between the lesion surface and
sites of deep invasive, or between differentiated and
undifferentiated portions of the same lesion.
Conclusions
In summary, loss of RKIP was associated with tumour
progression and poor survival in gastric cancer. Further-
more, negative RKIP expression combined with positive
p-ERK was an independent prognostic factor. Inhibition
of the MAPK signaling pathway may thus become an
important target for the treatment of gastric cancer.
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